BioPorto
The answer first
Does BioPorto beat the market?
No, BioPorto has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 29% of Nordic stocks
- Quality93
- Value8
- Trend22
No. 107 of 195 in healthcare
Max for seven days
Follow BioPorto with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about BioPorto
Your first answer is free, no account needed.
Do you own BioPorto, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with BioPorto and a few more. Free, no card.
Super Stock+44.6%In short
- BioPorto has fallen 11.2% over the past year, including dividends.
- Overall, BioPorto ranks better than 29% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 75.9%. The price is 99.5% below its peak now.
What do analysts think of BioPorto?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 29% of Nordic stocks.
No. 107 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 24 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.13
- Asset turnoverSales divided by everything the company owns0.34
- Return on equityProfit divided by equity+10.5%
- Cash conversionOperating cash flow divided by profit−8.40
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 145 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity5.5
- P/SPrice divided by sales12.2
- P/EPrice divided by earnings52.2
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 118 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−24.7%
- 6 months−22.9%
- 9 months−1.2%
- 12 months−11.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own BioPorto
4 funds we follow own BioPorto. The share is how much of the fund the stock makes up.
- Denmark4
From the funds' latest known holdings.
About BioPorto
BioPorto is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 44 employees.
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabe…


See the full analysis of BioPorto.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card